title: Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease.
abstract: OBJECTIVE
  To evaluate the relationship between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and inflammation in end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD).
  
  
  METHODS
  100 ESRD patients on maintenance HD (mean ± SD age: 52.3 ± 1.7 years, 52% were males) were included in this cross-sectional study. Data on patient demographics, dry weight, body mass index, duration of HD (months), etiology of ESRD, delivered dose of dialysis (spKt/V), complete blood count, blood biochemistry and inflammatory markers including hs-CRP (mg/L), TNF-α (pg/mL), NLR, and PLR were recorded in all patients and compared in patients with hs-CRP levels of ≤ 3 mg/L vs. > 3 mg/L. other study parameters were also recorded.
  
  
  RESULTS
  Compared to patients with lower hs-CRP levels, patients with hs-CRP levels of > 3 mg/L had significantly higher values for NLR (3.7 ± 0.2 vs. 2.7 ± 0.2, p < 0.01) and PLR (150.7 ± 6.9 vs. 111.8 ± 7.0, p < 0.001). Both NLR and PLR were positively correlated with hs-CRP (r = 0.333, p = 0.01 and r = 0.262, p = 0.001, respectively) and negatively correlated with transferrin saturation (%) (r = -0.418, p = 0.001 and r = -0.309, p = 0.002, respectively).
  
  
  CONCLUSIONS
  Our findings in a cohort of ESRD patients on maintenance HD revealed higher values for NLR and PLR in patients with higher levels of inflammation along with a significant positive correlation of both NLR and PLR with hs-CRP levels. Being a simple, relatively inexpensive and universally available method, whether or not calculation of NLR and PLR offers a plausible strategy in the evaluation of inflammation in ESRD patients in the clinical practice should be addressed in larger scale randomized and controlled studies.
authors.forename: Elbis
authors.initials: E
authors.lastname: Ahbap
authors.forename: Tamer
authors.initials: T
authors.lastname: Sakaci
authors.forename: Ekrem
authors.initials: E
authors.lastname: Kara
authors.forename: Tuncay
authors.initials: T
authors.lastname: Sahutoglu
authors.forename: Yener
authors.initials: Y
authors.lastname: Koc
authors.forename: Taner
authors.initials: T
authors.lastname: Basturk
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sevinc
authors.forename: Cuneyt
authors.initials: C
authors.lastname: Akgol
authors.forename: Arzu O
authors.initials: AO
authors.lastname: Kayalar
authors.forename: Zuhal A
authors.initials: ZA
authors.lastname: Ucar
authors.forename: Feyza
authors.initials: F
authors.lastname: Bayraktar
authors.forename: Abdulkadir
authors.initials: A
authors.lastname: Unsal
mesh_terms: D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000473:pathology*; D002097:C-Reactive Protein / Q000032:analysis; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D048909:Diabetes Complications / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000276:immunology; D018836:Inflammation Mediators / Q000097:blood; D033862:Iron-Binding Proteins / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000276:immunology / Q000628:therapy; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology*; D010976:Platelet Count; D006435:Renal Dialysis / Q000379:methods; D012709:Serum Albumin / Q000032:analysis; D014168:Transferrin / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D033862:Iron-Binding Proteins; D012709:Serum Albumin; D014168:Transferrin; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D005293:Ferritins